{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:57:58Z","timestamp":1783400278993,"version":"3.54.6"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3402102"],"award-info":[{"award-number":["2023YFC3402102"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2021CFA006"],"award-info":[{"award-number":["2021CFA006"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Teaching Fund of the Second Clinical College of Huazhong University of Science and Technology","award":["TJSZ2024061"],"award-info":[{"award-number":["TJSZ2024061"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Nab-paclitaxel is a standard second-line treatment for advanced gastric cancer, but the role of PD-1 inhibitors remains uncertain. This multicenter, randomized phase II trial evaluated the efficacy of nab-paclitaxel plus camrelizumab (Cam-NP) versus nab-paclitaxel alone (NP) in patients with advanced gastric adenocarcinoma resistant to prior treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients were randomized to receive either Cam-NP or NP until disease progression, intolerable toxicity, or consent withdrawal. The primary endpoint was the overall response rate (ORR), with secondary endpoints including progression-free survival (PFS), overall survival (OS), and safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sixty one patients were randomized, with 58 receiving treatments. At a median follow-up of 34.5 months, the Cam-NP group achieved a significantly higher ORR (33.3% vs. 10.7%; P\u2005=\u2005.039) and longer median PFS (5.62 vs. 4.21 months; P\u2005=\u2005.006). Median response duration also favored Cam-NP (4.64 vs. 2.96 months; P\u2005=\u2005.058). While the Cam-NP group showed a longer OS (9.8 vs. 7.2 months; P\u2005=\u2005.087), this was not statistically significant. The most common grade 3-4 adverse event was hematological toxicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Cam-NP significantly improved ORR and PFS compared to NP as a second-line treatment for advanced gastric adenocarcinoma. Larger studies and biomarker exploration are needed to validate these findings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov, NCT04294784, 03\/02\/2020.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf189","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T14:26:59Z","timestamp":1750775219000},"source":"Crossref","is-referenced-by-count":2,"title":["Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2918-9719","authenticated-orcid":false,"given":"Li","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan 430030 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of HubeiUniversity of Arts and Science , Xiangyang 441021 ,","place":["China"]},{"name":"Institute of Oncology, Hubei University of Arts and Science , Xiangyang 441021 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of HubeiUniversity of Arts and Science , Xiangyang 441021 ,","place":["China"]},{"name":"Institute of Oncology, Hubei University of Arts and Science , Xiangyang 441021 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Kuang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Guoyao Dongfeng General Hospital , Shiyan 442000 ,\u00a0","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Huang","sequence":"additional","affiliation":[{"name":"The First College of Clinical Medical Science, China Three Gorges University , Yichang 443000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture , Enshi 445000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglin","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan 430030 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2480-6332","authenticated-orcid":false,"given":"Hong","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan 430030 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"2025072309214948200_CIT0001","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025072309214948200_CIT0002","doi-asserted-by":"publisher","first-page":"101404","DOI":"10.1016\/j.eclinm.2022.101404","article-title":"The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study","volume":"47","author":"Morgan","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2025072309214948200_CIT0003","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"Al-Batran","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025072309214948200_CIT0004","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/annonc\/mdn717","article-title":"Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial","volume":"20","author":"Kang","year":"2009","journal-title":"Ann Oncol"},{"key":"2025072309214948200_CIT0005","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1093\/annonc\/mdn403","article-title":"Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie","volume":"19","author":"Al-Batran","year":"2008","journal-title":"Ann Oncol"},{"key":"2025072309214948200_CIT0006","doi-asserted-by":"publisher","first-page":"5660","DOI":"10.1200\/JCO.2005.17.376","article-title":"Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma","volume":"23","author":"Ajani","year":"2005","journal-title":"J Clin Oncol"},{"key":"2025072309214948200_CIT0007","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"2025072309214948200_CIT0008","doi-asserted-by":"publisher","first-page":"e1567","DOI":"10.1002\/onco.13826","article-title":"Treatment patterns and outcomes in Chinese patients with gastric cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE)","volume":"26","author":"Qin","year":"2021","journal-title":"Oncologist"},{"key":"2025072309214948200_CIT0009","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"2025072309214948200_CIT0010","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"2025072309214948200_CIT0011","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"2025072309214948200_CIT0012","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"2025072309214948200_CIT0013","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3390\/biomedicines10081822","article-title":"How chemotherapy affects the tumor immune microenvironment: a narrative review","volume":"10","author":"Merlano","year":"2022","journal-title":"Biomedicines"},{"key":"2025072309214948200_CIT0014","doi-asserted-by":"publisher","first-page":"e2201734","DOI":"10.1002\/advs.202201734","article-title":"Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency","volume":"9","author":"Li","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"2025072309214948200_CIT0015","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S2468-1253(16)30219-9","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial","volume":"2","author":"Shitara","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025072309214948200_CIT0016","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","article-title":"Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial","volume":"31","author":"Hironaka","year":"2013","journal-title":"J Clin Oncol"},{"key":"2025072309214948200_CIT0017","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","article-title":"Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial","volume":"15","author":"Ford","year":"2014","journal-title":"Lancet Oncol"},{"key":"2025072309214948200_CIT0018","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1200\/JCO.2003.08.058","article-title":"Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer","volume":"21","author":"Fuchs","year":"2003","journal-title":"J Clin Oncol"},{"key":"2025072309214948200_CIT0019","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1007\/s10147-020-01724-8","article-title":"Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303)","volume":"25","author":"Kobayashi","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"2025072309214948200_CIT0020","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s12029-023-00932-5","article-title":"Clinical outcomes for previously treated patients with advanced gastric or gastroesophageal junction cancer: a systematic literature review and meta-analysis","volume":"54","author":"Abderhalden","year":"2023","journal-title":"J Gastrointest Cancer"},{"key":"2025072309214948200_CIT0021","doi-asserted-by":"publisher","first-page":"6911","DOI":"10.21873\/anticanres.13068","article-title":"A Phase II Study of Tri-weekly Low-dose Nab-paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer","volume":"38","author":"Sato","year":"2018","journal-title":"Anticancer Res"},{"key":"2025072309214948200_CIT0022","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"2025072309214948200_CIT0023","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"2025072309214948200_CIT0024","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1007\/s00262-022-03174-9","article-title":"Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study","volume":"71","author":"Jing","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2025072309214948200_CIT0025","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41392-024-01773-9","article-title":"First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2025072309214948200_CIT0026","doi-asserted-by":"publisher","first-page":"e7006","DOI":"10.1002\/cam4.7006","article-title":"Efficacy and safety of camrelizumab combined with oxaliplatin and S-1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single-arm study","volume":"13","author":"Zhong","year":"2024","journal-title":"Cancer Med"},{"key":"2025072309214948200_CIT0027","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025072309214948200_CIT0028","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00280-018-3569-9","article-title":"Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis","volume":"81","author":"Iizumi","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025072309214948200_CIT0029","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/cas.12419","article-title":"Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer","volume":"105","author":"Sasaki","year":"2014","journal-title":"Cancer Sci"},{"key":"2025072309214948200_CIT0030","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: The ORIENT-16 Randomized Clinical Trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"2025072309214948200_CIT0031","doi-asserted-by":"publisher","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"Bmj"},{"key":"2025072309214948200_CIT0032","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025072309214948200_CIT0033","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s10120-019-01034-7","article-title":"A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data","volume":"23","author":"Chen","year":"2020","journal-title":"Gastric Cancer"},{"key":"2025072309214948200_CIT0034","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12885-023-10661-4","article-title":"Sintilimab plus apatinib and chemotherapy as second\u2011\/third-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: a prospective, single-arm, phase II trial","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Cancer"},{"key":"2025072309214948200_CIT0035","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025072309214948200_CIT0036","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/1078-0432.CCR-20-2291","article-title":"Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma","volume":"27","author":"Iorgulescu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025072309214948200_CIT0037","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12885-025-13591-5","article-title":"Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1\/PD-L1 antibody (PADDLE)","volume":"25","author":"Hirano","year":"2025","journal-title":"BMC Cancer"},{"key":"2025072309214948200_CIT0038","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1158\/1078-0432.CCR-20-3559","article-title":"Multicenter Phase I\/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer","volume":"27","author":"Nakajima","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025072309214948200_CIT0039","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf189\/63571189\/oyaf189.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyaf189\/63571189\/oyaf189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyaf189\/63571189\/oyaf189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T13:21:53Z","timestamp":1753276913000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf189\/8173022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf189","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7]]},"article-number":"oyaf189"}}